HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer

Journal of Clinical Oncology

Volumn 18, Issue 2, 2000, Pages 267-274

  Stark, Azadeh ^a   Hulka, Barbara S ^a   Joens, Scott ^a   Novotny, Debra ^a   Thor, Ann D ^a   Wold, Lester E ^a   Schell, Michael J ^a   Melton III, L Joseph ^a   Liu, Edison T ^a   Conway, Kathleen ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST DISEASE; CANCER RISK; CASE CONTROL STUDY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL;

EID: 18244412286     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.2.267     Document Type: Article

References (55)

1. Consensus Statement, Consensus meeting, New York, NY, October 3-5, 1985. Arch Pathol Lab Med 110:173, 1986
2. Black M, Barclay TH, Cutler SJ, et al: Association of atypical characteristics of benign breast lesions with subsequent risk of breast cancer. Cancer 29:338-343, 1972
3. London SJ, Connolly JL, Schnitt SJ, et al: A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941-944, 1992
4. Page DL, Dupont WD: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146-151, 1985
5. Bodian CA, Perzin KH, Lattes R, et al: Prognostic significance of benign proliferative breast disease. Cancer 71:3896-3907, 1993
6. Rosai J: Borderline epithelial lesions of the breast. Am J Surg Pathol 15:209-221, 1991
7. Schnitt SJ, Wang HH: Histologic sampling of grossly benign breast biopsies: How much is enough? Am J Surg Pathol 13:505-512, 1989
8. Schnit SJ, Connolly JL, Tavassoli FA, et al: Inter-observer reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 16:1133-1143, 1992
9. Zhou D, Battifora H, Yokota J, et al: Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res 47:6123-6125, 1987
10. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 235:177-181, 1987
11. van de Vijver MJ, Peters JL, Moor WJ, et al: Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245, 1988
12. Liu ET, Thor AD, He M, et al: The HER-2 (c-erbB-2) oncogene is frequently amplified in in-situ carcinomas of the breast. Oncogene 7:1027-1032, 1992
13. Allred DG, Clark GM, Molina R, et al: Overexpression of HER-2/neu and its relationship with other prognostic factors changes during the progression of in situ to invasive breast cancer. Hum Pathol 23:974-979, 1992
14. Pechoux C, Chardonnet Y, Noël P: Immunohistochemical studies on c-erbB-2 oncoprotein expression in paraffin embedded tissue in invasive and non-invasive human breast lesions. Anticancer Res 14:1343-1350, 1994
15. Wells CA, McGregor IL, Makunura CN, et al: Apocrine adenosis: A precursor of aggressive breast cancer? J Clin Pathol 48:737-742, 1995
16. Lizard-Nacol S, Lidereau R, Collin F, et al: Benign breast disease: Absence of genetic alterations at several loci implicated in breast cancer malignancy. Cancer Res 55:4416-4419, 1995
17. Multi-Center Study Group: Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction. JAMA 267:2609-2615, 1992
18. Schiffman MH, Schatskin A: A test of reliability is critically important to molecular epidemiology: An example from studies of human papillomavirus infection and cervical neoplasia. Cancer Res 54:1944-1947, 1994
19. Hillsenbeck SG, Clark GM: Surrogate end points in chemoprevention of breast cancer: Guidelines for evaluation of new biomarkers. J Cell Biochem 17:205-211, 1993
20. Allred DG, O'Connell P, Fuqua SAW: Biomarkers in early breast neoplasia. J Cell Biochem 17:125-131, 1993
21. Thor AD, Schwartz LH, Koemer FC, et al: Analysis of c-erbB-2 expression in breast carcinoma with clinical follow-up. Cancer Res 49:7147-7152, 1989
22. Corbett IP, Henry JA, Angus B, et al: NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 161:15-25, 1990
23. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1265, 1994
24. Frye RA, Benz CC, Liu E: Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 4:1153-1157, 1989
25. Kreipe H., Feist H, Fischer L, et al: Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res 53:1956-1961, 1993
26. Gasparini G, Pozza F, Meli S, et al: Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Res 11:2015-2022, 1991
27. Barbareschi M, Leonardi E, Mauri FA, et al: p53 and c-erbB-2 protein expression in breast carcinomas: An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Anat Pathol 98:408-418, 1992
28. Kommoss F, Colley M, Hart CE, et al: In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-β-subunit. Mol Cell Probes 4:11-23, 1990
29. Heatley M, Maxwell P, Whiteside C, et al: c-erbB-2 oncogene product expression depends on tumour type and is related to oestrogen receptor and lymph node status in human breast carcinoma. Pathol Res Pract 189:261-266, 1993
30. Parkes HC, Lillycrop K, Howell A, et al: c-erbB2 mRNA expression in human breast tumours: Comparison with c-erbB2 DNA amplification and correlation with prognosis. Br J Cancer 61:39-45, 1990
31. Coene ED, Schlefout V, Winkler RA, et al: Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer. Virchows Arch 430:365-372, 1997
32. Lodato RF, Maguire HC Jr, Greene MI, et al: Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in-situ and atypical ductal hyperplasia of the breast. Mod Pathol 3:449-454, 1990
33. Allred DC, Clark GM, Molina R, et al: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974-979, 1992
34. Gusterson BA, Machin LG, Gullick WJ, et al: c-erbB-2 expression in benign and malignant breast disease. Br J Cancer 58:453-457, 1988
35. Rohan TE, Hartwick W, Miller AB, et al: Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst 90:1262-1269, 1998
36. Friedrichs K, Lohmann D, Höfler H: Detection of HER-2 oncogene amplification in breast cancer by differential polymerase chain reaction from single cryosections. Virchows Archiv B Cell Pathol lncl Mol Pathol 64:209-212, 1993
37. Robertson KW, Reeves JR, Smith G, et al: Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 56:3823-3830, 1996
38. Persons DL, Borelli KA, Hsu PH: Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridzation. Mod Pathol 10:720-727, 1997
39. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707-712, 1989
40. Grooteclaes M, Vernimmen D, Plaza S, et al: A new cis element is involved in the HER2 gene overexpression in human breast cancer cells. Cancer Res 59:2527-2531, 1999
41. Miller S, Suen T-C, Hung T-C: Mechanisms of deregulated HER2/neu expression in breast cancer cell lines. Int J Oncol 4:599-608, 1994
42. Bosher JM, Williams T, Hurst HC: The developmentally regulated transcription factor AP-2 is involved in the c-erbB-2 overexpression in human mammary adenocarcinoma. Proc Natl Acad Sei USA 92:744-747, 1995
43. Osher J, Totty N, Hsuan J, et al: A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 13:1701-1707, 1996
44. Press MF, Pike MC, Chazin VR, et al: Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993
45. Press MF, Hung G, Godolphin W, et al: Sensitivity of HER-2/ neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
46. Bonner RF, Emmert-Buck M, Cole K, et al: Laser capture microdissection: Molecular analysis of tissue. Science 278:1481-1483, 1997
47. HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 55:5400-5407, 1995
48. Tsuda H, Hirohashi S, ShimosatoY, et al: Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: A retrospective analysis of 176 cases. Cancer 65:1794-1800, 1990
49. Ciocca DR, Fujimura FK, Tandon AK, et al: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancer. J Natl Cancer Inst 84:1279-1282, 1992
50. Malamou-Mitsi VD, Krikoni OC, Agnantis NJ: Clonal analysis by PCR and RFLP in breast cancer and precancerous lesions, preliminary data. Anticancer Res 16:3943-3948, 1996
51. O'Connell P, Pekkel V, Fuqua S, et al: Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 32:5-12, 1994
52. Lakhani SR, Slack DN, Hamoudi RA, et al: Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab Invest 74:129-135, 1996
53. Millikan R, Hulka B, Thor A, et al: p53 mutations in benign breast tissue. J Clin Oncol 13:2293-2300, 1995
54. Rosenberg CL, de las Morenas A, Huang K, et al: Detection of monoclonal microsatellite alterations in atypical breast hyperplasia. J Clin Invest 98:1095-1100, 1996
55. Rosenberg CL, Larson PS, Romo JD, et al: Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Hum Pathol 28:214-219, 1997